Intellipharmaceutics International Inc. (IPCI)

[AngeloFoca]

to reiterate:

Seroquel XR total market is now $775 million - for every 1% market share that MNK captures it equals $7.75 million to MNK and IPCI yearly.

I believe IPCI's royalty on Seroquel XR to be 40% but will use 30% to be conservative... so every 1% market share equals $2.3 million to IPCI.

I believe there are presently 6 companies selling Seroquel XR... so if MNK gets it's share of the market... it could/should capture 16% market share... which would/could translate into $36.8 million per year to IPCI.

Sounds like fairy land to most here... but lets say they get 20% royalties... then their yearly royalty will be ~ $24 million... based on 16% market share.

OK... let's knock down the market penetration to 8% instead of 16% - and at 20% royalty payment it's still $12 million a year.

I don't know how far backward you want me to bend to show the potential here... but this is not wishful thinking... it is fact... it is on the market NOW!!!

The unknown here is how efficiently and aggressively will MNK be... what % share of the market will they capture... and how soon.

I have no idea how marketing generics works... but I believe it's more like a commodity and if say Walgreen or CVS has ongoing relationship with MNK then they may even be required to purchase from them... would love to hear from someone in the know how this works.

But even at 20% royalty... IPCI will receive $1.5 million per 1% of market share - my personal belief is they will receive a minimum 30% and likely a 40% royalty payment.

Ohhh... and Pristiq which is already partnered with MNK and may be approved any day now... also has the same economics.

The runway has been made longer... but I still believe IPCI will eventually take off.